HCAT

Health Catalyst, Inc.
2 filings tracked
healthcarehealthcare itSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Health Catalyst is aggressively transitioning from a services-heavy model to a lean, technology-centric business. While the first quarter of 2026 saw a dip in total revenue to $70.8 million, the underlying shift is promising.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

The narrative of a "lean tech pivot" masks a deteriorating core business characterized by shrinking revenues and persistent churn.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every HCAT filing.

Start Free Trial

Synthesis (Verdict & Resolution)

Health Catalyst finds itself at a critical juncture, balancing a necessary structural transformation against severe short-term execution risks. The company is successfully shifting its revenue mix toward higher-margin technology subscriptions, but this progress is being offset by the painful reality of the DOS-to-Ignite migration, which is triggering client churn and reducing ARR. The financial results present a dichotomy: improving operational efficiency and Adjusted EBITDA growth versus a massive GAAP net loss driven by a necessary goodwill impairment. Ultimately, the investment thesis hinges on whether the "Project Nexus" workforce reductions and the tailored client retention playbooks can stop the bleeding of at-risk revenue before the $160 million debt burden becomes unsustainable. The market is now pricing Health Catalyst not as a growth story, but as a turnaround play where the primary goal is the stabilization of the recurring revenue base and the successful completion of its platform migration by 2027.

Selected Quarter

Core Takeaway

The company is successfully reducing its cost base and increasing the proportion of tech revenue, but it is fighting a significant battle against client churn during its platform migration.

Investor Lens

The trade-off is between the improved operational efficiency (higher margins) and the high risk of further revenue attrition during the migration window.

Watch Next

The progress of the DOS-to-Ignite migration and the impact of Project Nexus on Q2 2026 operating expenses.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.15Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 11

Total revenue declined 11% YoY due to platform migration churn and down-selling.

earnings miss
70%
bullishMay 11

Total gross margin expanded to 39% from 36% as the company pivots to technology revenue.

margin expansion
60%
neutralMay 11

Transition of CEO Dan Burton and implementation of Project Nexus restructuring.

management change
40%
bearishMay 11

High-interest variable rate term loan of $160M creates significant interest expense pressure.

debt restructure
50%
bearishMay 11

Total revenue declined 11% YoY due to platform migration churn and down-selling.

earnings miss
70%
bullishMay 11

Total gross margin expanded to 39% from 36% as the company pivots to technology revenue.

margin expansion
60%
neutralMay 11

Transition of CEO Dan Burton and implementation of Project Nexus restructuring.

management change
40%
bearishMay 11

High-interest variable rate term loan of $160M creates significant interest expense pressure.

debt restructure
50%

Filing History

10-QMay 11, 2026
Expand Sequence

Health Catalyst finds itself at a critical juncture, balancing a necessary structural transformation against severe short-term execution risks. The company is successfully shifting its revenue mix toward higher-margin technology subscriptions, but this progress is being offset by the painful reality of the DOS-to-Ignite migration, which is triggering client churn and reducing ARR. The financial results present a dichotomy: improving operational efficiency and Adjusted EBITDA growth versus a massive GAAP net loss driven by a necessary goodwill impairment. Ultimately, the investment thesis hinges on whether the "Project Nexus" workforce reductions and the tailored client retention playbooks can stop the bleeding of at-risk revenue before the $160 million debt burden becomes unsustainable. The market is now pricing Health Catalyst not as a growth story, but as a turnaround play where the primary goal is the stabilization of the recurring revenue base and the successful completion of its platform migration by 2027.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.